315 related articles for article (PubMed ID: 18006136)
1. PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators.
Gonzalez FJ; Shah YM
Toxicology; 2008 Apr; 246(1):2-8. PubMed ID: 18006136
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation.
Shah YM; Morimura K; Yang Q; Tanabe T; Takagi M; Gonzalez FJ
Mol Cell Biol; 2007 Jun; 27(12):4238-47. PubMed ID: 17438130
[TBL] [Abstract][Full Text] [Related]
3. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha.
Cheung C; Akiyama TE; Ward JM; Nicol CJ; Feigenbaum L; Vinson C; Gonzalez FJ
Cancer Res; 2004 Jun; 64(11):3849-54. PubMed ID: 15172993
[TBL] [Abstract][Full Text] [Related]
4. Time course investigation of PPARalpha- and Kupffer cell-dependent effects of WY-14,643 in mouse liver using microarray gene expression.
Woods CG; Kosyk O; Bradford BU; Ross PK; Burns AM; Cunningham ML; Qu P; Ibrahim JG; Rusyn I
Toxicol Appl Pharmacol; 2007 Dec; 225(3):267-77. PubMed ID: 17950772
[TBL] [Abstract][Full Text] [Related]
5. WY-14,643 induced cell proliferation and oxidative stress in mouse liver are independent of NADPH oxidase.
Woods CG; Burns AM; Bradford BU; Ross PK; Kosyk O; Swenberg JA; Cunningham ML; Rusyn I
Toxicol Sci; 2007 Aug; 98(2):366-74. PubMed ID: 17483499
[TBL] [Abstract][Full Text] [Related]
6. Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis.
Hays T; Rusyn I; Burns AM; Kennett MJ; Ward JM; Gonzalez FJ; Peters JM
Carcinogenesis; 2005 Jan; 26(1):219-27. PubMed ID: 15447978
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic effects of the continuous exposure to peroxisome proliferator WY-14,643 in mouse liver are dependent upon peroxisome proliferator activated receptor alpha.
Pogribny IP; Tryndyak VP; Woods CG; Witt SE; Rusyn I
Mutat Res; 2007 Dec; 625(1-2):62-71. PubMed ID: 17586532
[TBL] [Abstract][Full Text] [Related]
8. Toxic effects of fumonisin in mouse liver are independent of the peroxisome proliferator-activated receptor alpha.
Voss KA; Liu J; Anderson SP; Dunn C; Miller JD; Owen JR; Riley RT; Bacon CW; Corton JC
Toxicol Sci; 2006 Jan; 89(1):108-19. PubMed ID: 16221962
[TBL] [Abstract][Full Text] [Related]
9. Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis.
Morimura K; Cheung C; Ward JM; Reddy JK; Gonzalez FJ
Carcinogenesis; 2006 May; 27(5):1074-80. PubMed ID: 16377806
[TBL] [Abstract][Full Text] [Related]
10. Comparison of dose-response relationships for induction of lipid metabolizing and growth regulatory genes by peroxisome proliferators in rat liver.
Belury MA; Moya-Camarena SY; Sun H; Snyder E; Davis JW; Cunningham ML; Vanden Heuvel JP
Toxicol Appl Pharmacol; 1998 Aug; 151(2):254-61. PubMed ID: 9707502
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the species-specificity of peroxisome proliferators in rat and human hepatocytes.
Ammerschlaeger M; Beigel J; Klein KU; Mueller SO
Toxicol Sci; 2004 Apr; 78(2):229-40. PubMed ID: 14976357
[TBL] [Abstract][Full Text] [Related]
12. Evidence that reduction of hepatocyte growth factor (HGF) is not required for peroxisome proliferator-induced hepatocyte proliferation.
Kiss A; Ortiz-Aguayo R; Sharp R; Merlino G; Thorgeirsson SS; Gonzalez FJ; Peters JM
Carcinogenesis; 2001 Jun; 22(6):975-9. PubMed ID: 11375907
[TBL] [Abstract][Full Text] [Related]
13. A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines.
Doull J; Cattley R; Elcombe C; Lake BG; Swenberg J; Wilkinson C; Williams G; van Gemert M
Regul Toxicol Pharmacol; 1999 Jun; 29(3):327-57. PubMed ID: 10388618
[TBL] [Abstract][Full Text] [Related]
14. Is peroxisome proliferation an obligatory precursor step in the carcinogenicity of di(2-ethylhexyl)phthalate (DEHP)?
Melnick RL
Environ Health Perspect; 2001 May; 109(5):437-42. PubMed ID: 11401753
[TBL] [Abstract][Full Text] [Related]
15. Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis.
Yeldandi AV; Rao MS; Reddy JK
Mutat Res; 2000 Mar; 448(2):159-77. PubMed ID: 10725470
[TBL] [Abstract][Full Text] [Related]
16. Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver.
Peters JM; Aoyama T; Cattley RC; Nobumitsu U; Hashimoto T; Gonzalez FJ
Carcinogenesis; 1998 Nov; 19(11):1989-94. PubMed ID: 9855014
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte-restricted constitutive activation of PPAR alpha induces hepatoproliferation but not hepatocarcinogenesis.
Yang Q; Ito S; Gonzalez FJ
Carcinogenesis; 2007 Jun; 28(6):1171-7. PubMed ID: 17331954
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?
Peters JM; Cheung C; Gonzalez FJ
J Mol Med (Berl); 2005 Oct; 83(10):774-85. PubMed ID: 15976920
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences.
Holden PR; Tugwood JD
J Mol Endocrinol; 1999 Feb; 22(1):1-8. PubMed ID: 9924174
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis.
Peters JM; Rusyn I; Rose ML; Gonzalez FJ; Thurman RG
Carcinogenesis; 2000 Apr; 21(4):823-6. PubMed ID: 10753222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
